From March 2013, transcutaneous vagus nerve stimulation (t-VNS) with cerbomed's Nemos will be available to Italian epilepsy patients. To address the Italian market, cerbomed is co-operating with Marvamed. Co-operations with further European distributors should follow in the course of 2013.
t-VNS is addressed to patients suffering from various difficult-to-treat neurological and psychiatric diseases. The therapy uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and therefore can be stimulated through the skin with electrical impulses. With Nemos, cerbomed developed and patented a stimulator and a dedicated ear electrode for treatment of epilepsy with t-VNS. The stimulator, which is connected with the ear electrode, sends out the electrical impulses. With t-VNS Nemos, a targeted stimulation of the vagus nerve is possible without the need of a surgery.
In 2010, cerbomed received the CE mark for the t-VNS for the treatment of epilepsies and depression, and in 2012 for the treatment of pain. Currently, two clinical studies are being carried out regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine.
Nemos is currently available for treating epilepsy in Germany and Austria, and in Italy from March. Forthcoming co-operations with other distributors should make Nemos available to epilepsy patients in the UK, France and Spain.